Biomed Central Ltd

SHERPA: Unknown

People

  1. Budhu
    Budhu
  2. Postow
    Postow
  3. Liu
    Liu
  4. Mangarin
    Mangarin
  5. Panageas
    Panageas
  6. Hirschhorn Cymerman
    Hirschhorn Cymerman
  7. Wong
    Wong
  8. Zhong
    Zhong
  9. Deng
    Deng
  10. Gupta
    Gupta

Groups

  1. Department of Medicine (83)
  2. GSK Faculty (83)
  3. Melanoma and Immunotherapeutics Service (83)
  4. Solid Tumor Oncology Division (83)
  5. Sloan Kettering Institute Postdocs (43)
  6. Melanoma Disease Management Team (25)
  7. Hematology-Oncology Fellows (21)
  8. Hematologic Malignancies, Division of (14)
  9. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (12)
  10. Epidemiology and Biostatistics (12)
Search Within
  1. "Jedd Wolchok"
Formats
  1. Meeting Abstract (67)
  2. Journal Article (16)
Groups
  1. Department of Medicine (83)
  2. GSK Faculty (83)
  3. Melanoma and Immunotherapeutics Service (83)
  4. Solid Tumor Oncology Division (83)
  5. Sloan Kettering Institute Postdocs (43)
  6. Melanoma Disease Management Team (25)

More Groups

People
  1. Jedd Wolchok (83)
  2. Taha Merghoub (47)
  3. Sadna Budhu (21)
  4. Michael Postow (18)
  5. Roberta Zappasodi (18)
  6. Cailian Liu (11)

More People

Years
  1. 2022 (10)
  2. 2021 (10)
  3. 2020 (8)
  4. 2019 (2)
  5. 2018 (8)
  6. 2017 (14)

More Years

Publications
  1. Journal for ImmunoTherapy of Cancer (81)
  2. Journal of Translational Medicine (2)

Results (83)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Signal-regulatory protein alpha (SIRPĪ±) confers tumor cell resistance to anti-tumor immunity
    Meeting Abstract

    Weng, C. H.; Hamadene, L.; Eghbali, S.; Venkatesh, D.; Monette, S.; Mangarin, L.; Samaan, F.; Liu, C.; Holland, P.; Wolchok, J.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Lag3 blockade in combination with GITR improves anti-tumor immune responses in a preclinical melanoma model
    Meeting Abstract

    Maniyar, R.; Zappasodi, R.; Elhanati, Y.; St Jean, S.; Carrasco, S.; Greenbaum, B.; Wolchok, J.; Merghoub, T.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Apr-246 induces an increase in tumor immunogenicity in a p53 independent manner
    Meeting Abstract

    Venkatesh, D.; Michels, J.; Lu, C.; Budhu, S.; George, M.; Ouerfelli, O.; Abrahmsen, L.; Zappasodi, R.; Wolchok, J.; Merghoub, T.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • LDH inhibition improves response to CTLA-4 blockade by enhancing effector T cell activity and impairing regulatory T cell suppression
    Meeting Abstract

    Verma, S.; Serganova, I.; Budhu, S.; Dong, L.; Mangarin, L.; Ko, M.; Blasberg, R.; Zappasodi, R.; Wolchok, J.; Merghoub, T.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Immune checkpoint blockade enhances cyclophosphamide induced anti-tumor immunity in a preclinical melanoma model
    Meeting Abstract

    George, M.; Betof, A.; Merghoub, T.; Hamadene, L.; Hirschhorn, D.; Houghton, A.; Wolchok, J.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Predicting primary resistance and exploring mechanisms in patients with advanced melanoma treated with immune checkpoint inhibitors (ICIS)
    Meeting Abstract

    Georgina Long, A. O.; Tang, T.; Apfel, A.; Paulucci, D.; Chasalow, S.; Tenney, D.; Fusaro, G.; Schadendorf, D.; Tawbi, H.; Hodi, F. S.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Repeat dosing of oncolytic adenovirus ONCOS-102 is associated with enhanced and persistent immune responses and improved systemic activity in anti-PD-1 resistant/refractory (R/R) melanoma
    Meeting Abstract

    Shoushtari, A.; Ottesen, L.; Levitsky, V.; Hansen, T. B.; Hornyak, T.; Olszanski, A.; Nyakas, M.; Wolchok, J.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Development of optimized car T cells for therapy of glioblastoma
    Meeting Abstract

    Khan, J.; Cai, W.; Yang, Y.; Dong, L.; Hopland, K.; Yu, K. K. H.; Freeman, R.; Purdon, T.; Tabar, V.; Merghoub, T.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Immunogenic landscape and therapeutic targeting of mutant NRAS "public" neoantigens
    Meeting Abstract

    Etxeberria, I.; Banks, L.; Chandran, S.; Correa, A.; Novak, B.; Fleischman, J.; Drilon, A.; Wolchok, J.; Merghoub, T.; Klebanoff, C.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: Clinical outcomes and translational biomarker analyses
    Journal Article

    Friedman, C. F.; Spencer, C.; Cabanski, C. R.; Panageas, K. S.; Wells, D. K.; Ribas, A.; Tawbi, H.; Tsai, K.; Postow, M.; Shoushtari, A.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save